Sabag Mark's most recent trade in Teva- Pharmaceutical Industries Ltd. - ADR was a trade of 337,915 Ordinary Shares done at an average price of $18.0 . Disclosure was reported to the exchange on May 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Teva- Pharmaceutical Indus... | Mark Sabag | See "Remarks" | Sale of securities on an exchange or to another person at price $ 18.04 per share. | 08 May 2025 | 337,915 | 150,996 (0%) | 0% | 18.0 | 6,097,304 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Mark Sabag | See "Remarks" | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 62,893 | 62,893 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Mark Sabag | See "Remarks" | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 23,765 | 488,911 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Mark Sabag | See "Remarks" | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 23,765 | 0 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Mark Sabag | See "Remarks" | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 183,169 | 0 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Mark Sabag | See "Remarks" | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 183,169 | 465,146 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Mark Sabag | See "Remarks" | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 33,512 | 263,376 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Mark Sabag | See "Remarks" | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 33,512 | 33,512 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Mark Sabag | See "Remarks" | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 18,601 | 281,977 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Mark Sabag | See "Remarks" | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 18,601 | 55,803 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Mark Sabag | See "Remarks" | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 24,900 | 229,864 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Mark Sabag | See "Remarks" | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 24,900 | 49,801 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Mark Sabag | See "Remarks" | Sale of securities on an exchange or to another person at price $ 16.25 per share. | 12 Feb 2025 | 177,626 | 204,964 (0%) | 0% | 16.3 | 2,886,565 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Mark Sabag | EVP, International Markets | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 183,169 | 183,169 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Mark Sabag | EVP, International Markets | Sale of securities on an exchange or to another person at price $ 13.52 per share. | 05 Mar 2024 | 100,000 | 382,590 (0%) | 0% | 13.5 | 1,352,090 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Mark Sabag | EVP, International Markets | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 58,133 | 482,590 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Mark Sabag | EVP, International Markets | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 58,133 | 0 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Mark Sabag | EVP, International Markets | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 23,764 | 23,765 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Mark Sabag | EVP, International Markets | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 23,764 | 424,457 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Mark Sabag | EVP, International Markets | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2024 | 74,404 | 74,404 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Mark Sabag | EVP, International Markets | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 33,512 | 67,024 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Mark Sabag | EVP, International Markets | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 33,512 | 400,693 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Mark Sabag | EVP, International Markets | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 24,900 | 367,181 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Mark Sabag | EVP, International Markets | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 24,900 | 74,701 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Sabag Mark | EVP, International Markets | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 20,599 | 0 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Mark Sabag | EVP, International Markets | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 20,599 | 342,281 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Mark Sabag | EVP, International Markets | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2024 | 58,133 | 58,133 | - | - | Restricted Share Units |